Effects of Levosimendan on the right heart function in patients with acute decompensated heart failure

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009974

Enrollment

Unknown

Registered

2016-11-23

Start date

2017-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute decompensated heart failure

Interventions

levosimendan group:Routine treatment + levosimendan

Control group:Routine treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: NYHA classification III to IV, and/or LVEF<45%.

Exclusion criteria

Exclusion criteria: 1. Acute or chronic infectious diseases; 2. Acute myocardial infarction; 3. Serious liver and kidney dysfunction; 4. Malignant arrhythmia; 5. Cardiac shock; 6. Refused to participate.

Design outcomes

Primary

Measure	Time frame
BNP;cTnI;MACE;RVEDV;RVESV;RVEF;s’;Tei index;	—

Secondary

Measure	Time frame
LVEDV;LVESV;LVEF;E/E’;E/A;	—

Countries

China

Contacts

Public ContactWang Yanbo

Second Hospital of Hebei Medical University

doctorwangyanbo@126.com+86 13931858363

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026